News
After a sluggish 2025, biotech IPOs have roared back to life. Fueled by resilient stock performances and improving market sentiment, the total number of public debuts so far this year has already eclipsed 2025’s total.
FEATURED STORIES
As antibody-drug conjugates advance and move into earlier lines of treatment, drug developers have to build gentler therapies that don’t just extend survival but improve it.
FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Novartis expands its optogenetics portfolio with the acquisition of Arctos Medical, cementing its commitment to optogenetics-based therapies to restore vision to patients with advanced blindness.
In September 20, 2021, the United States marked a grisly milestone, recording more American deaths from COVID-19 than died from the 1918-1919 Spanish flu pandemic.
The FDA did not identify any deficiencies related to the manufacturing of the asset. However, the agency did identify deficiencies at the facility of a CMO Verrica is working with.
The Phase III COSMIC-311 trial for CABOMETYX delivered favorable final results in terms of objective response rate, progression-free survival, median overall survival, and safety.
MiroBio’s pipeline involves checkpoint receptor pathways, not for immuno-oncology indications, but for the treatment of autoimmune diseases.
Zai Lab Limited calls itself a growing global biopharmaceutical company and is continuing to live up to that claim with its latest expansion announcement.
Sheila Gujrathi, M.D. will join the board of directors as executive chair, while Jörn Drappa, M.D., Ph.D. will serve as chief medical officer.
During the past two years, fundraising and investment in biotechnology have reached record levels.
Mirati Therapeutics tapped David Meek, the former chief executive officer of Ipsen, as its new CEO. He replaces company founder Charles Baum.
The company announced Friday that clinical studies have been placed on hold following the development of tumors in mice in a non-clinical study.